Kalverdijk, LJ;
Bachmann, CJ;
Aagaard, L;
Burcu, M;
Glaeske, G;
Hoffmann, F;
Petersen, I;
... Zito, JM; + view all
(2017)
A multi-national comparison of antipsychotic drug use in children and adolescents, 2005-2012.
A multi-national comparison of antipsychotic drug use in children and adolescents, 2005–2012
, 11
, Article 55. 10.1186/s13034-017-0192-1.
Preview |
Text
A multi-national comparison of antipsychotic drug use in children and adolescents, 2005-2012.pdf - Published Version Download (988kB) | Preview |
Abstract
Over the last decades, an increase in antipsychotic (AP) prescribing and a shift from first-generation antipsychotics (FGA) to second-generation antipsychotics (SGA) among youth have been reported. However, most AP prescriptions for youth are off-label, and there are worrying long-term safety data in youth. The objective of this study was to assess multinational trends in AP use among children and adolescents. A repeated cross-sectional design was applied to cohorts from varied sources from Denmark, Germany, the Netherlands, the United Kingdom (UK) and the United States (US) for calendar years 2005/2006–2012. The annual prevalence of AP use was assessed, stratified by age group, sex and subclass (FGA/SGA). The prevalence of AP use increased from 0.78 to 1.03% in the Netherlands’ data, from 0.26 to 0.48% in the Danish cohort, from 0.23 to 0.32% in the German cohort, and from 0.1 to 0.14% in the UK cohort. In the US cohort, AP use decreased from 0.94 to 0.79%. In the US cohort, nearly all ATP dispensings were for SGA, while among the European cohorts the proportion of SGA dispensings grew to nearly 75% of all AP dispensings. With the exception of the Netherlands, AP use prevalence was highest in 15–19 year-olds. So, from 2005/6 to 2012, AP use prevalence increased in all youth cohorts from European countries and decreased in the US cohort. SGA were favoured in all countries’ cohorts.
| Type: | Article |
|---|---|
| Title: | A multi-national comparison of antipsychotic drug use in children and adolescents, 2005-2012 |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1186/s13034-017-0192-1 |
| Publisher version: | https://doi.org/10.1186/s13034-017-0192-1 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Pediatrics, Psychiatry, Adolescents, Children, Antipsychotic drugs, Atypical, Denmark, Germany, Netherlands, UK, USA, Pharmacoepidemiology, AUTISM SPECTRUM DISORDERS, 2ND-GENERATION ANTIPSYCHOTICS, UNITED-STATES, PRIMARY-CARE, TARDIVE-DYSKINESIA, INSURED CHILDREN, PUBLIC-ATTITUDES, MEDICATIONS, BEHAVIOR, RISK |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health > Primary Care and Population Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Population, Policy and Practice Dept |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10029734 |
Archive Staff Only
 |
View Item |
